- Home
- ALKS vs RYTM Comparison
ALKS vs RYTM Comparison
Compare ALKS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKS
- RYTM
- Stock Information
- Founded
- ALKS 1987
- RYTM 2008
- Country
- ALKS Ireland
- RYTM United States
- Employees
- ALKS N/A
- RYTM N/A
- Industry
- ALKS Biotechnology: Pharmaceutical Preparations
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- ALKS Health Care
- RYTM Health Care
- Exchange
- ALKS Nasdaq
- RYTM Nasdaq
- Market Cap
- ALKS 5.1B
- RYTM 5.9B
- IPO Year
- ALKS 1991
- RYTM 2017
- Fundamental
- Price
- ALKS $26.13
- RYTM $86.45
- Analyst Decision
- ALKS Strong Buy
- RYTM Strong Buy
- Analyst Count
- ALKS 13
- RYTM 13
- Target Price
- ALKS $40.23
- RYTM $89.77
- AVG Volume (30 Days)
- ALKS 2.0M
- RYTM 1.0M
- Earning Date
- ALKS 07-29-2025
- RYTM 08-05-2025
- Dividend Yield
- ALKS N/A
- RYTM N/A
- EPS Growth
- ALKS N/A
- RYTM N/A
- EPS
- ALKS 2.09
- RYTM N/A
- Revenue
- ALKS $1,513,770,000.00
- RYTM $136,863,000.00
- Revenue This Year
- ALKS N/A
- RYTM $37.47
- Revenue Next Year
- ALKS $4.18
- RYTM $71.16
- P/E Ratio
- ALKS $12.40
- RYTM N/A
- Revenue Growth
- ALKS N/A
- RYTM 48.88
- 52 Week Low
- ALKS $25.56
- RYTM $40.61
- 52 Week High
- ALKS $36.45
- RYTM $94.80
- Technical
- Relative Strength Index (RSI)
- ALKS 29.30
- RYTM 66.82
- Support Level
- ALKS $26.05
- RYTM $86.25
- Resistance Level
- ALKS $27.29
- RYTM $92.14
- Average True Range (ATR)
- ALKS 0.87
- RYTM 3.68
- MACD
- ALKS -0.31
- RYTM -0.14
- Stochastic Oscillator
- ALKS 1.65
- RYTM 72.31
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.